Matterworks | Resources

DECEMBER 2024	Pyxis™ Receives The Analytical Scientist Innovation Award 2024 Matterworks receives The Analytical Scientist Innovation Award 2024 for Pyxis, a "smart application of AI for the analysis of LC-MS data." ARTICLE
JUNE 2024	Matterworks Launches Pyxis™ - First AI-Powered, Turn-Key Platform for Identification and Absolute Quantitation from Mass Spectrometry Data Matterworks is pleased to announce the official launch of Pyxis, our AI-powered platform for untargeted absolute quantitation of analytes. ARTICLE
MAY 2024	Matterworks Announces Updates to Leadership Team Matterworks is pleased to announce the appointments of Jennifer M. Campbell, Ph.D. to the position of Chief Scientific Officer and Niall O'Connor to the position of Chief Technology Officer. ARTICLE
FEBRUARY 2024	Matterworks Announces Board Updates Matterworks is pleased to announce the appointments of Michael Lavin, a Managing Partner at Germin8 Ventures and Dr. Shubhra Jain, Head of Health-Tech Venture Investments at Tarsadia, as Board Members. ARTICLE
MARCH 2023	2023 Life Science Review Award Matterworks has been recognized in the Top 10 Biotech Startups - 2023 by Life Science Review. ARTICLE
DECEMBER 2022	Matterworks Announces CEO Appointment and Board Updates Matterworks, Inc., developers of the world’s most powerful AI platform for modeling real-time biology to accelerate the discovery, development, and manufacturing of life sciences technologies, including biologics and gene therapies, today announces CEO appointment and updates to its Board of Directors. PRESS RELEASE
AUGUST 2022	Matterworks Awarded NIIMBL Project 5.2 Grant Matterworks is awarded a grant to participate in NIIMBL Project 5.2. With support from Eli Lilly and Sartorius our novel AI-powered Pyxis™ Metabolomics Platform will demonstrate biological insight in bioprocessing through the rapid, absolute quantitation of critical metabolites that impact titer and CQAs. ARTICLE
APRIL 2022	Matterworks Announces Updates To Its Board Of Directors Matterworks, Inc., developers of the world’s most powerful metabolomics platform, which accelerates the discovery, development, and manufacturing of biologics and gene therapies, today announces updates to its Board of Directors. PRESS RELEASE